A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9-15-Year-Old Girls

Pediatric Infectious Disease Journal

Volumn 34, Issue 9, 2015, Pages 992-998

  Vesikari, Timo ^a   Brodszki, Nicholas ^b   Van Damme, Pierre ^c   Diez Domingo, Javier ^d   Icardi, Giancarlo ^e   Petersen, Lone Kjeld ^f   Tran, Clément ^g   Thomas, Stéphane ^g   Luxembourg, Alain ^h   Baudin, Martine ^g  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d Area of Vaccines Research   (Spain)

^e UNIVERSITY OF GENOA   (Italy)

^f AARHUS UNIVERSITY HOSPITAL   (Denmark)

^g SANOFI PASTEUR   (France)

^h MERCK RESEARCH LABORATORIES   (United States)

Author keywords

cervical cancer; genital warts; human papillomavirus; immunogenicity; vaccine

Indexed keywords

9 VALENT HUMAN PAPILLOMAVIRUS L1 VIRUS LIKE PARTICLE VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS LIKE PARTICLE VACCINE; WART VIRUS VACCINE;

ADOLESCENT; ANTIBODY RESPONSE; ARTICLE; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PAPILLOMAVIRUS INFECTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SEROLOGY; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; BLOOD; CLINICAL TRIAL; COMPLICATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; IMMUNIZATION; IMMUNOLOGY; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; UTERINE CERVICAL NEOPLASMS;

ADOLESCENT; ANTIBODIES, VIRAL; CHILD; DOUBLE-BLIND METHOD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; IMMUNOASSAY; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84940027111     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000773     Document Type: Article

References (56)

1. de Sanjosé S, Alemany L, Ordi J, et al; HPV VVAP Study Group. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer. 2013;49:3450-3461.
2. de Sanjose S, Quint WG, Alemany L, et al; Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11:1048-1056.
3. Garland SM, Steben M, Sings HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis. 2009;199:805-814.
4. Hatch KD. A3. Vaginal intraepithelial neoplasia (VAIN). Int J Gynaecol Obstet. 2006;94(Suppl 1):S40-S43.
5. Kjaer SK, Tran TN, Sparen P, et al. The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. J Infect Dis. 2007;196:1447-1454.
6. Palefsky JM. Anal squamous intraepithelial lesions: relation to HIV and human papillomavirus infection. J Acquir Immune Defic Syndr. 1999;21 (Suppl 1):S42-S48.
7. Picconi MA, Eiján AM, Distéfano AL, et al. Human papillomavirus (HPV) DNA in penile carcinomas in Argentina: analysis of primary tumors and lymph nodes. J Med Virol. 2000;61:65-69.
8. Srodon M, Stoler MH, Baber GB, et al. The distribution of low and high-risk HPV types in vulvar and vaginal intraepithelial neoplasia (VIN and VaIN). Am J Surg Pathol. 2006;30:1513-1518.
9. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-19.
10. Kreimer AR, Clifford GM, Boyle P, et al. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005;14:467-475.
11. Acay R, Rezende N, Fontes A, et al. Human papillomavirus as a risk factor in oral carcinogenesis: a study using in situ hybridization with signal amplification. Oral Microbiol Immunol. 2008;23:271-274.
12. Kirrander P, Kolaric A, Helenius G, et al. Human papillomavirus prevalence, distribution and correlation to histopathological parameters in a large Swedish cohort of men with penile carcinoma. BJU Int. 2011;108:355-359.
13. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007;121:621-632.
14. Yanofsky VR, Patel RV, Goldenberg G. Genital warts: a comprehensive review. J Clin Aesthet Dermatol. 2012;5:25-36.
15. Baylor NW. June 8, 2006 Approval Letter-Human papillomavirus quadrivalent (types 6, 11, 16, 18) vaccine, recombinant [US Food and Drug Administration Website]; 2006. Available at: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm111283.htm. Accessed April 1, 2014.
16. European Medicines Agency. Gardasil® human papillomavirus vaccine [types 6,11,16,18] (recombinant, adsorbed) [European Public Assessment Report; European Medicines Agency website]; 2014. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000703/human-med-000805.jsp. Accessed April 1, 2014.
17. Garland SM, Hernandez-Avila M, Wheeler CM, et al; Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928-1943.
18. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med. 2011;364:401-411.
19. Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915-1927.
20. Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet. 2007;369:1693-1702.
21. Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011;365:1576-1585.
22. Arnheim-Dahlström L, Pasternak B, Svanström H, et al. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ. 2013;347:f5906.
23. Block SL, Brown DR, Chatterjee A, et al. Clinical trial and postlicensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine. Pediatr Infect Dis J. 2010;29:95-101.
24. Chao C, Klein NP, Velicer CM, et al. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J Intern Med. 2012;271:193-203.
25. Gee J, Naleway A, Shui I, et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine. 2011;29:8279-8284.
26. Grimaldi-Bensouda L, Guillemot D, Godeau B, et al; PGRx-AID Study Group. Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects. J Intern Med. 2014;275:398-408.
27. Klein NP, Hansen J, Chao C, et al. Safety of quadrivalent human papillomavirus vaccine administered routinely to females. Arch Pediatr Adolesc Med. 2012;166:1140-1148.
28. Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA. 2009;302:750-757.
29. Paavonen J, Jenkins D, Bosch FX, et al; HPV PATRICIA Study Group. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007;369:2161-2170.
30. Baldur-Felskov B, Dehlendorff C, Munk C, et al. Early impact of human papillomavirus vaccination on cervical neoplasia-nationwide follow-up of young Danish women. J Natl Cancer Inst. 2014;106:djt460.
31. Brotherton JM, Fridman M, May CL, et al. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet. 2011;377:2085-2092.
32. Crowe E, Pandeya N, Brotherton JM, et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ. 2014;348:g1458.
33. Powell SE, Hariri S, Steinau M, et al. Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions. Vaccine. 2012;31:109-113.
34. Kahn JA, Brown DR, Ding L, et al. Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction. Pediatrics. 2012;130:e249-e256.
35. Markowitz LE, Hariri S, Lin C, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis. 2013;208:385-393.
36. Tabrizi SN, Brotherton JM, Kaldor JM, et al. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis. 2012;206:1645-1651.
37. Baandrup L, Blomberg M, Dehlendorff C, et al. Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program. Sex Transm Dis. 2013;40:130-135.
38. Bauer HM, Wright G, Chow J. Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007-2010. Am J Public Health. 2012;102:833-835.
39. Leval A, Herweijer E, Arnheim-Dahlström L, et al. Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability. J Infect Dis. 2012;206:860-866.
40. Nsouli-Maktabi H, Ludwig SL, Yerubandi UD, et al. Incidence of genital warts among U.S. service members before and after the introduction of the quadrivalent human papillomavirus vaccine. MSMR. 2013;20:17-20.
41. Read TR, Hocking JS, Chen MY, et al. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect. 2011;87:544-547.
42. Schiller JT, Castellsagué X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012;30 (Suppl 5):F123-F138.
43. Serrano B, Alemany L, Tous S, et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer. 2012;7:38.
44. Joura EA, Ault KA, Bosch FX, et al. Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease. Cancer Epidemiol Biomarkers Prev. 2014;23:1997-2008.
45. Alemany L, Saunier M, Tinoco L, et al; HPV VVAP study group. Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples. Eur J Cancer. 2014;50:2846-2854.
46. Alemany L, Saunier M, Alvarado-Cabrero I, et al; HPV VVAP Study Group. Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer. 2015;136:98-107.
47. Van Damme P, Leroux-Roels G, Simon P, et al. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials. Vaccine. 2014;32:3694-3705.
48. Joura EA, Giuliano AR, Iversen OE, et al; Broad Spectrum HPV Vaccine Study. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372:711-723.
49. World Health Organization. Guidelines to Assure the Quality, Safety and Efficacy of Recombinant Human Papillomavirus Virus-like Particle Vaccines. Geneva, Switzerland: World Health Organization; 2006 (WHO/BS/06.2050).
50. Van Damme P, Olsson SE, Block S, et al. Immunogenicity and safety of a 9-valent HPV vaccine. Pediatrics. 2015;136:e28-e39.
51. Roberts C, Green T, Hess E, et al. Development of a human papillomavirus competitive immunoassay for nine HPV types. Hum Vaccin Immunother. 2014;10:2174-2103.
52. Sanofi Pasteur MSD. Summary of product characteristics-HBVax Pro 10 mcg [electronic Medicines Compendium website]. 2011. Available at: http://www.medicines.org.uk/EMC/medicine/9847/SPC/HBVAXPRO+10mcg/. Accessed April 1, 2014.
53. Giuliano AR, Lazcano-Ponce E, Villa L, et al. Impact of baseline covariates on the immunogenicity of a quadrivalent (types 6, 11, 16, and 18) human papillomavirus virus-like-particle vaccine. J Infect Dis. 2007;196:1153-1162.
54. Sanofi Pasteur MSD. Summary of product characteristics-Gardasil [electronic medicines compendium website]; 2013. Available at: http://www.medicines.org.uk/emc/medicine/19016/SPC/GARDASIL/. Accessed April 1, 2014.
55. Glaxo Smith Kline Vaccine HPV Study Group, Romanowski B, de Borba PC, Naud PS, et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet. 2009;374:1975-1985.
56. Dobson SR, McNeil S, Dionne M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA. 2013;309:1793-1802.